Cargando…
Hormonal Male Contraception: Getting to Market
Rates of unplanned pregnancies are high and stagnant globally, burdening women, families and the environment. Local limitations placed upon contraceptive access and abortion services exacerbate global disparities for women. Despite survey data suggesting men and their partners are eager for expanded...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203677/ https://www.ncbi.nlm.nih.gov/pubmed/35721718 http://dx.doi.org/10.3389/fendo.2022.891589 |
_version_ | 1784728748594036736 |
---|---|
author | Page, Stephanie T. Blithe, Diana Wang, Christina |
author_facet | Page, Stephanie T. Blithe, Diana Wang, Christina |
author_sort | Page, Stephanie T. |
collection | PubMed |
description | Rates of unplanned pregnancies are high and stagnant globally, burdening women, families and the environment. Local limitations placed upon contraceptive access and abortion services exacerbate global disparities for women. Despite survey data suggesting men and their partners are eager for expanded male contraceptive options, efforts to develop such agents have been stymied by a paucity of monetary investment. Modern male hormonal contraception, like female hormonal methods, relies upon exogenous progestins to suppress the hypothalamic-pituitary-gonadal axis, in turn suppressing testicular testosterone production and sperm maturation. Addition of an androgen augments gonadotropin suppression, more effectively suppressing spermatogenesis in men, and provides androgenic support for male physiology. Previous contraceptive efficacy studies in couples have shown that hormonal male methods are effective and reversible. Recent efforts have been directed at addressing potential user and regulatory concerns by utilizing novel steroids and varied routes of hormone delivery. Provision of effective contraceptive options for men and women is an urgent public health need. Recognizing and addressing the gaps in our contraceptive options and engaging men in family planning will help reduce rates of unplanned pregnancies in the coming decades. |
format | Online Article Text |
id | pubmed-9203677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92036772022-06-18 Hormonal Male Contraception: Getting to Market Page, Stephanie T. Blithe, Diana Wang, Christina Front Endocrinol (Lausanne) Endocrinology Rates of unplanned pregnancies are high and stagnant globally, burdening women, families and the environment. Local limitations placed upon contraceptive access and abortion services exacerbate global disparities for women. Despite survey data suggesting men and their partners are eager for expanded male contraceptive options, efforts to develop such agents have been stymied by a paucity of monetary investment. Modern male hormonal contraception, like female hormonal methods, relies upon exogenous progestins to suppress the hypothalamic-pituitary-gonadal axis, in turn suppressing testicular testosterone production and sperm maturation. Addition of an androgen augments gonadotropin suppression, more effectively suppressing spermatogenesis in men, and provides androgenic support for male physiology. Previous contraceptive efficacy studies in couples have shown that hormonal male methods are effective and reversible. Recent efforts have been directed at addressing potential user and regulatory concerns by utilizing novel steroids and varied routes of hormone delivery. Provision of effective contraceptive options for men and women is an urgent public health need. Recognizing and addressing the gaps in our contraceptive options and engaging men in family planning will help reduce rates of unplanned pregnancies in the coming decades. Frontiers Media S.A. 2022-06-03 /pmc/articles/PMC9203677/ /pubmed/35721718 http://dx.doi.org/10.3389/fendo.2022.891589 Text en Copyright © 2022 Page, Blithe and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Page, Stephanie T. Blithe, Diana Wang, Christina Hormonal Male Contraception: Getting to Market |
title | Hormonal Male Contraception: Getting to Market |
title_full | Hormonal Male Contraception: Getting to Market |
title_fullStr | Hormonal Male Contraception: Getting to Market |
title_full_unstemmed | Hormonal Male Contraception: Getting to Market |
title_short | Hormonal Male Contraception: Getting to Market |
title_sort | hormonal male contraception: getting to market |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203677/ https://www.ncbi.nlm.nih.gov/pubmed/35721718 http://dx.doi.org/10.3389/fendo.2022.891589 |
work_keys_str_mv | AT pagestephaniet hormonalmalecontraceptiongettingtomarket AT blithediana hormonalmalecontraceptiongettingtomarket AT wangchristina hormonalmalecontraceptiongettingtomarket |